argenx SE header image

argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2026-04-24)
EUR 666.20-2.80%

argenx SE
UMushroom community rating:

star star star star star
4.86 3 votes No rating yet
NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

25.3%1Y
88.9%3Y
174%5Y

Performance

35.0%1Y
40.0%3Y
38.6%5Y

Volatility

Market cap

48469 M

Market cap (USD)

Daily traded volume (Shares)

83,268

Daily traded volume (Shares)

1 day high/low

600 / 594.2

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.86

3 votes
Performance:
starstarstarstarstar
4.71
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
4.86
Nature:
starstarstarstarstar
3.57
Laura Sofie Tohver
United Kingdom, 11 Nov 2025
star star star star star
Emerging technology and nice returns
Viktor Stockel
Switzerland, 30 Oct 2025
star star star star star
Argenx SE is a commercial-stage, global biopharmaceutical company focused on immunology, particularly therapies for severe autoimmune diseases.
Claudia Stadelmann
Switzerland, 05 Mar 2025
star star star star star
Geheimtipp belgisches Biotech mit spannender Pipeline

EQUITIES OF THE SAME SECTOR

Koninklijke Philips NV
Koninklijke Philips NV Koninklijke Philips NV Valor: 1106818
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.77%EUR 23.29
SK hynix Inc
SK hynix Inc SK hynix Inc Valor: 18382960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.38%EUR 744.00
Brady Corp
Brady Corp Brady Corp Valor: 913942
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.69%USD 80.70
TEMENOS LTD
TEMENOS LTD TEMENOS LTD Valor: 1245391
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.07%CHF 74.50
Array Technologies Inc
Array Technologies Inc Array Technologies Inc Valor: 57373259
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 8.11
Cogent Communications Holdings Inc
Cogent Communications Holdings Inc Cogent Communications Holdings Inc Valor: 1886547
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.09%USD 24.47
N-able Inc
N-able Inc N-able Inc Valor: 112382956
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.50%USD 5.18
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc Mirum Pharmaceuticals Inc Valor: 48639108
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.50%USD 91.49
TripAdvisor Inc
TripAdvisor Inc TripAdvisor Inc Valor: 14491714
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.04%USD 11.19
EnviTec Biogas AG
EnviTec Biogas AG EnviTec Biogas AG Valor: 3241377
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.80%EUR 25.20